Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

Fig. 2

DOR, PFS, and OS for the patients involved. A Duration of response for each individual patients based on IRC assessment per RECIST v1.1 (N = 119). B Kaplan–Meier estimates of PFS in the full-analysis set based on IRC assessment per RECIST v1.1. C Kaplan–Meier estimates of DOR for the patients achieved PR/CR based on IRC assessment per RECIST v1.1 (N = 24). D Kaplan–Meier estimates of OS in the full-analysis set. E Kaplan–Meier estimates of PFS for different primary subtypes based on IRC assessment per RECIST v1.1. F Kaplan–Meier estimates of OS for different primary subtypes

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us